Imatinib is manufactured by Novartis and is used to treat cancer. ## Compulsory licenses A compulsory licence application is currently pending for Imatinib in Colombia. The application was submitted by civil society. Compulsory licenses have been issued for Imatinib in the following instance: ### Colombia issued on November 01, 2014 [[Colombia]]'s provisions on compulsory licences can be in Decree 1074 of 2015. Compulsory licenses in Colombia can be granted under several circumstances, including: - Public Interest or National Emergency: The government may declare certain situations as matters of public interest or national emergency, justifying the issuance of a compulsory license to ensure public access to essential products or technologies. - Anti-Competitive Practices: If a patent holder engages in anti-competitive practices, such as abuse of dominant position or restrictive trade practices, a compulsory license can be issued to rectify the situation. - Failure to Exploit the Patent: If the patent is not being exploited within the national territory, and the lack of exploitation affects public interest, a compulsory license may be granted to promote the utilization of the patented invention. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/18421 ). ### Thailand issued on January 01, 2008 [[Thailand]]'s provisions on compulsory licences can be in the Patent Act B.E. 2522 (1979). There are four main grounds for issuing a compulsory licence: - Non-working / inadequate “working” Patent not locally produced or imported, or sold at unreasonably high price relative to domestic demand. - Dependent patents Use of a later patent requiring the earlier patent’s invention. - Public non-commercial/government use For public health, environmental conservation, food/medicine shortages, etc. - National emergency / public interest Covers war, epidemics (e.g., HIV/AIDS, SARS, bird flu), national emergencies. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/3807 ). However, a compulsory license has not been executed for Imatinib in this case because: donation. ## Other products issued by the same manufacturer [[Mycophenolic acid]] [[Imatinib]] [[Letrozole]] ## Other products for the same disease [[Erlotinib]] [[Letrozole]] [[Sunitinib, erlotinib]] [[Gemcitabine]] [[Trastuzumab-Emtansine]] [[Pertuzumab]] [[Dasatinib]] [[Docetaxel]] [[Sorafenib Tosylate]] [[Sunitinib]]